• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Keegan Robert J

    6/8/23 9:21:28 PM ET
    $NOVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NOVN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    KEEGAN ROBERT J

    (Last) (First) (Middle)
    C/O NOVAN, INC.
    4020 STIRRUP CREEK DRIVE, SUITE 110

    (Street)
    DURHAM NC 27703

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Novan, Inc. [ NOVN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/06/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/07/2023 M 36,101(1) A $0 42,404 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (2) 06/06/2023 A 103,092 (3) (3) Common Stock 103,092 $0 103,092 D
    Restricted Stock Units (2) 06/07/2023 M 36,101 (4) (4) Common Stock 36,101 $0 0 D
    Explanation of Responses:
    1. The Reporting Person was granted restricted stock units ("RSUs") on June 7, 2022. Each RSU represented a contingent right to receive one share of the Issuer's Common Stock. 36,101 RSUs fully vested on June 7, 2023 and were settled in shares of the Issuer's Common Stock.
    2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
    3. The RSUs shall be fully vested on the first anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service as of the vesting date.
    4. The RSUs fully vested on June 7, 2023.
    Remarks:
    /s/ John M. Gay, by power of attorney 06/08/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NOVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NOVN

    DatePrice TargetRatingAnalyst
    9/24/2021$28.00 → $24.00Buy
    HC Wainwright & Co.
    7/9/2021$30.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $NOVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Novan with a new price target

      HC Wainwright & Co. reiterated coverage of Novan with a rating of Buy and set a new price target of $24.00 from $28.00 previously

      9/24/21 6:07:00 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Novan with a new price target

      Cantor Fitzgerald initiated coverage of Novan with a rating of Overweight and set a new price target of $30.00

      7/9/21 6:35:54 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Novan with a new price target

      HC Wainwright & Co. reiterated coverage of Novan with a rating of Buy and set a new price target of $28.00 from $20.00 previously

      6/14/21 6:19:32 AM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NOVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sanders Machelle

      4 - Novan, Inc. (0001467154) (Issuer)

      6/27/23 6:30:05 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by John A. Donofrio

      4 - Novan, Inc. (0001467154) (Issuer)

      6/8/23 9:22:44 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Gay John M.

      4 - Novan, Inc. (0001467154) (Issuer)

      6/8/23 9:22:29 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NOVN
    SEC Filings

    See more
    • Novan Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Material Modification to Rights of Security Holders

      8-K - NVN Liquidation, Inc. (0001467154) (Filer)

      1/30/24 4:47:37 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novan Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NVN Liquidation, Inc. (0001467154) (Filer)

      1/26/24 4:38:13 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novan Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NVN Liquidation, Inc. (0001467154) (Filer)

      12/21/23 4:13:26 PM ET
      $NOVN
      Biotechnology: Pharmaceutical Preparations
      Health Care